CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
We had previously demonstrated the role of CD103 integrin on lung tumor-infiltrating lymphocyte (TIL) clones in promoting specific TCR-mediated epithelial tumor cell cytotoxicity. However, the contribution of CD103 on intratumoral T cell distribution and functions and the prognosis significance of TIL subpopulations in non–small cell lung carcinoma (NSCLC) have thus far not been systematically addressed. In this study, we show that an enhanced CD103+ TIL subset correlates with improved early stage NSCLC patient survival and increased intraepithelial lymphocyte infiltration. Moreover, our results indicate that CD8+CD103+ TIL, freshly isolated from NSCLC specimens, display transcriptomic and phenotypic signatures characteristic of tissue-resident memory T cells and frequently express PD-1 and Tim-3 checkpoint receptors. This TIL subset also displays increased activation-induced cell death and mediates specific cytolytic activity toward autologous tumor cells upon blockade of the PD-1–PD-L1 interaction. These findings emphasize the role of CD8+CD103+ tissue-resident memory T cells in promoting intratumoral CTL responses and support the rationale for using anti–PD-1 blocking Ab to reverse tumor-induced T cell exhaustion in NSCLC patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further research revealed that the presence of CD103+CD8+ TILs is a positive prognostic marker in several cancers [269-272].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [270]
In the citing paper
“Previous studies demonstrated that enhanced CD8+CD103+ TRM TILs correlate with improved survival in patients with early stage NSCLC18 and with other types of cancer19.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [18]
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“types of advanced solid tumors, including NSCLC (43, 44).”
BackgroundTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · cited 1×
“both molecules has been reported to transmit a death signal to T cells (40, 41).”
BackgroundUpregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Trautmann, L., Janbazian, L., Chomont, N., Said, E. A., Gimmig, S., Bessette, B., Boulassel, M.-R., Delwart, E., Sepulveda, H., Balderas, R. S., et al. (2006) · Nature Medicine · doi:10.1038/nm1482 · Cited by 1,565
The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin
Mackay, L. K., Rahimpour, A., Ma, J. Z., Collins, N., Stock, A. T., Hafon, M.-L., Vega-Ramos, J., Lauzurica, P., Mueller, S. N., Stefanovic, T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2744 · Cited by 1,331 · cited 5×
“Indeed, downregulation of SIP1 was observed in CD103CD8 TRM T cells (18) and appeared to be required for their retention in peripheral tissues (28).”
BackgroundInfluentialFourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307 · cited 1×
“Among these inhibitory receptors, CTLA-4, PD-1, and Tim3 appeared to be associated with T cell exhaustion in chronic viral infections (35–38) and tumor progression (39).”
BackgroundPD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111 · cited 1×
“In the latter and present studies, CD103 T cells expressed high levels of PD-1, which has been defined as a biomarker of tumor-specific T cells (33).”
BackgroundSkin infection generates non-migratory memory CD8+ TRM cells providing global skin immunity
Jiang, X., Clark, R. A., Liu, L., Wagers, A. J., Fuhlbrigge, R. C., & Kupper, T. S. (2012) · Nature · doi:10.1038/nature10851 · Cited by 891 · cited 1×
“TRM T cells are highly activated T lymphocytes that reside within a variety of peripheral tissues, including intestine (17, 20), brain (21), skin (22, 23), and lung”
Background
Cited by
Items 401–500 of 661
Du, C., Ni, M., Jiang, J., Kong, F., Zhai, R., Lv, Y., Hu, C., & Ying, H. (2022) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-021-07192-8 · Cited by 11
“Especially the decrease in the subpopulation of CD8+T cell suggests that the host tends to have an inadequate immunological reaction to tumor cell [8].”
BackgroundMultimodal delineation of a layer of effector function among exhausted CD8 T cells in tumors
Ray, A., Bassette, M. A., Hu, K. H., Pass, L. F., Courau, T., Samad, B., Combes, A. J., Johri, V., Davidson, B. R., Wai, K. C., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adt3537 · Cited by 11
CD103 blockade impair anti-CTLA-4 immunotherapy in oral cancer
Xiao, Y., Mao, L., Yang, Q., Wang, S., Wu, Z., Wan, S., Zhang, M.-J., & Sun, Z. (2023) · Oral Oncology · doi:10.1016/j.oraloncology.2023.106331 · Cited by 10
Eribulin mesylate exerts antitumor effects via CD103
Oya, K., Nakamura, Y., Watanabe, R., Tanaka, R., Ichimura, Y., Kubota, N., Matsumura, Y., Tahara, H., Okiyama, N., Fujimoto, M., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2218782 · Cited by 11
Time-resolved role of P2X4 and P2X7 during CD8+ T cell activation
Brock, V. J., Lory, N. C., Möckl, F., Birus, M., Stähler, T., Woelk, L.-M., Jaeckstein, M. Y., Heeren, J., Koch‐Nolte, F., Rissiek, B., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1258119 · Cited by 10
Wei, X., Gu, L., & Heng, W. (2020) · Oncology Letters · doi:10.3892/ol.2020.12350 · Cited by 12
Single-Cell Profiling of the Immune Atlas of Tumor-Infiltrating Lymphocytes in Endometrial Carcinoma
Jiang, F., Jiao, Y., Yang, K., Mao, M., Yu, M. Y., Cao, D., & Xiang, Y. (2022) · Cancers · doi:10.3390/cancers14174311 · Cited by 10
Kume, M., Kiyohara, E., Matsumura, Y., Koguchi‐Yoshioka, H., Tanemura, A., Hanaoka, Y., Taminato, M., Tashima, H., Tomita, K., Kubo, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.651048 · Cited by 10
Toh, J. W. T., Ferguson, A. L., Spring, K. J., Mahajan, H., & Palendira, U. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i4.238 · Cited by 11
Rodríguez, E., Zwart, E. S., Affandi, A. J., Verhoeff, J., de Kok, M., Boyd, L. N. C., Meijer, L. L., Large, T. Y. S. L., Olesek, K., Giovannetti, E., et al. (2024) · Cancer Science · doi:10.1111/cas.16147 · Cited by 9
Immune Regulation and Immune Therapy in Melanoma: Review with Emphasis on CD155 Signalling
Wu, L., Park, S.-H., Jakobsson, H., Shackleton, M. J., & Möller, A. (2024) · Cancers · doi:10.3390/cancers16111950 · Cited by 9
“PD-1 is highly co-expressed with CD103, one of the tissue-resident markers on intra-epithelial CD8 + TIL in human ovarian cancer and non-small-cell lung cancer [118,119].”
BackgroundTilsed, C. M., Brotman, J. J., O’Brien, S., Lee, B., Moon, E. K., & Albelda, S. (2025) · ImmunoHorizons · doi:10.1093/immhor/vlaf013 · Cited by 9
“Whereas we 14 and others 15 have described the presence and function of T RM in lung cancers, there is very little information about this T cell subset in the large group of cancer patients who have malignant pleural effusions (MPE).”
InfluentialXiong, H., & Shen, Z. (2024) · International Journal of Cancer · doi:10.1002/ijc.34940 · Cited by 9
Significance of Herpesvirus Entry Mediator Expression in Human Colorectal Liver Metastasis
Sasaki, Y., Hokuto, D., Inoue, T., Nomi, T., Yoshikawa, T., Matsuo, Y., Koyama, F., & Sho, M. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07625-z · Cited by 9
Lubbers, J. M., Ważyńska, M. A., van Rooij, N., Kol, A., Workel, H. H., Plat, A., Paijens, S. T., Vlaming, M. R., Spierings, D. C. J., Elsinga, P. H., et al. (2022) · Cancers · doi:10.3390/cancers14081924 · Cited by 9
PHA eludes macrophage suppression to activate CD8+ T cells
Lomakova, Y. D., Londregan, J., Maslanka, J. R., Goldman, N., Somerville, J. E., & Riggs, J. E. (2018) · Immunobiology · doi:10.1016/j.imbio.2018.10.004 · Cited by 11
Abdkarimi, S., Soofiyani, S. R., Elham, G., Abdolahi, H. M., Safarzadeh, E., & Baradaran, B. (2020) · European Journal of Cancer Care · doi:10.1111/ecc.13268 · Cited by 9
Tissue-Resident Lymphocytes: Implications in Immunotherapy for Hepatocellular Carcinoma
Han, J. W., & Yoon, S. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010232 · Cited by 9
“Previous study showed that CD8+ TILs can directly kill autologous tumor in vitro [42].”
BackgroundWan, Y., Wang, X., Liu, T., Fan, T., Zhang, Z., Wang, B., Zhang, B., Tian, Z., Mao, T., Gong, Z., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3931 · Cited by 11
Wu, L. M., Yang, L., Sun, J., Zhao, M., Geng, J., Cao, F., Chen, Q., Yan, Y., Yang, H., Sun, X., et al. (2025) · Pathology & Oncology Research · doi:10.3389/pore.2025.1612229 · Cited by 10
O'Kane, G. M., Mesci, A., Jang, R., Barry, A. S., Bocaya, C. M., Boukhaled, G. M., Acton, H. J., Doddington, D., Rodrigo, R., Chan, L. M. L., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101658 · Cited by 13
“25,26 We found a higher abundance of peripheral CD57+Granzyme B+ NK cells was associated with poorer PFS. Interestingly, data regarding the prognostic value of peripheral NK cells is conflicting in other solid tumors.”
Kol, A., Fan, X., Ważyńska, M. A., van Duijnhoven, S. M. J., Giesen, D., Plat, A., van Eenennaam, H., Elsinga, P. H., Nijman, H. W., & de Bruyn, M. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004877 · Cited by 8
“14–19 For example, tumors are frequently enriched for virus-specific bystander T cells that have no contributing effect to the anti-cancer activity.”
Sun, H., Han, X., Du, Z., Chen, G., Guo, T., Xie, F., Gu, W., & Shi, Z. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02737-0 · Cited by 10
Jiao, L., Tao, Y., Ding, H., Wu, F., Liu, Y., Li, C., & Li, F. (2024) · 3 Biotech · doi:10.1007/s13205-024-04053-z · Cited by 8
“Tumor-infiltrating lymphocytes (TIL) are significantly associated with 5-year survival in NSCLC, whereas lower expression of lymphocytes in tumors is usually considered to be associated with a poorer prognosis in early-stage NSCLC (Goc et al. 2014; Djenidi et al. 2015).”
Li, Z., Lin, X., Yang, Y., Tian, M. L., Zhang, L., Huang, F., Xiao, W., Wei, Z., & Tian, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-88126-w · Cited by 8
Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors.
Aspeslagh, S., Marabelle, A., Soria, J., & Armand, J. (2015) · PubMed · doi:10.3978/j.issn.2304-3865.2015.12.06 · Cited by 8
“As for other cancer types, the presence of different effector T cells subsets seemed to be correlated with long-term OS (3,4).”
BackgroundAdhikary, S., Hoskin, T. L., Stallings‐Mann, M. L., Arshad, M., Frost, M. H., Winham, S. J., Peña, A., Lee, D. J., Murphy, L. M., Rakoff, M., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05493-5 · Cited by 8
Prognostic impact of tumor-infiltrating lymphocytes in non-small cell lung carcinomas
Mlika, M., Saidi, A., Mejri, N., Abdennadher, M., Haddouchi, C., Labidi, S., Khiari, H., Boussen, H., Hsaïri, M., & Mezni, F. E. (2021) · Asian Cardiovascular and Thoracic Annals · doi:10.1177/02184923211042129 · Cited by 8
Gültekin, M., Esen, C. S. B., Özdemir, D. A., Yildirim, S. Y., Yüce, D., Usubutün, A., & Yıldız, F. (2022) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-022-06687-x · Cited by 9
Tissue-Resident Cytolytic Innate Lymphocytes in Cancer
Nixon, B. G., & Li, M. O. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701124 · Cited by 8
The Clinical Significance of Mesenteric Lymphocytes in Human Colorectal Cancer
Wu, Z., Wang, F., Li, L., Yao, Y., Long, J., Luo, Q., Zhao, Z., Li, W., Cao, J., & Lian, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.685577 · Cited by 8
Ullah, M. A., Islam, N. N., Moin, A. T., Park, S. H., & Kim, B. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.935286 · Cited by 8
Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies
Chen, Y., Qi, F., Sun, C., Jiang, P., Xue, X., Yang, X., Li, X., He, X., Wang, Y., & Zhang, T. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241312501 · Cited by 8
Tissue Resident Memory Cells: Friend or Foe?
Chude, C. F., Uzonna, J. E., & Arsenio, J. (2025) · Immunology · doi:10.1111/imm.70024 · Cited by 7
Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises
Ashi, M. O., Mami‐Chouaib, F., & Corgnac, S. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00111 · Cited by 7
Self-citationFang, J., Lei, J., He, B., Wu, Y., Chen, P., Sun, Z., Wu, N., Huang, Y., Wei, P., Yin, L., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04978-2 · Cited by 7
“Furthermore, previous studies reported that Trm cell infiltration was strongly correlated with survival and dominated the protective response in HGSOC [52] and urothelial cancer [49], breast cancer [51], endometrial cancer [54], and lung cancer [10].”
ResultKang, X., Zhao, S., Lin, S., Li, J., & Wang, S. (2024) · Oncology Letters · doi:10.3892/ol.2024.14501 · Cited by 7
Tumor immunity requires border patrol to fight the enemy within
Amsen, D., Hombrink, P., & van Lier, R. A. W. (2017) · Nature Immunology · doi:10.1038/ni.3792 · Cited by 7
Min, J., Dong, F., Wu, P., Xu, X., Wu, Y., Tan, Y., Yang, F., & Chai, Y. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s316994 · Cited by 7
“suggesting that total CD8 T cells do not correlate with survival in NSCLC patients unless CD8 T cells are present in the tumor tissue.(15) Several clinical studies have shown that tumorinfiltrating CD8 TRMs are positively associated with lung cancer patient prognosis,(14,15) and the evidence suggests that CD8 TRMs are…”
BackgroundHuang, Y., Zhou, L., Zhang, H., Zhang, L., Xi, X., & Sun, Y. (2022) · Cellular Immunology · doi:10.1016/j.cellimm.2022.104502 · Cited by 8
DNA methylation profiling in early lung adenocarcinoma to predict response to immunotherapy
Smet, C. D. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-96 · Cited by 7
“Comparison of the two immunological phenotypes revealed no difference in overall survival, an observation that was in disagreement with previous studies where hot tumors correlated with a better prognosis (11,12).”
Young, S. A., Griego-Fullbright, C., Wagner, A., Chargin, A., Patterson, B. K., & Chabot‐Richards, D. (2018) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqy063 · Cited by 7
Tumor-infiltrating lymphocyte expansion protocols for adoptive cell therapy in cancer
Manzano, D. T., Subhi‐Issa, N., Pereiro-Rodríguez, A., Cade, I. G. L., González, M. M., Fernández‐Arquero, M., Segura, P. P., Ujaldón‐Miró, C., Sánchez‐Ramón, S., Ocaña, A., et al. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01112-2 · Cited by 8
“This correlation has also been observed in non-small cell lung carcinoma, where the presence of CD103 + TILs is linked to improved patient survival [86].”
Xing, Y., Zhou, Y., Wang, R., Chen, J., Yang, L., Meng, X., Wang, J., Ouyang, Q., Zhao, J., Chen, F., et al. (2025) · Developmental Cell · doi:10.1016/j.devcel.2025.08.003 · Cited by 6
CD8 T Cell Vaccines and a Cytomegalovirus-Based Vector Approach
Šustić, M., Brdovčak, M. C., Krmpotić, A., & Jonjić, S. (2021) · Life · doi:10.3390/life11101097 · Cited by 7
“More importantly, a higher frequency of tissue resident cells was associated with increased survival in breast [96], lung [97], and ovarian cancers [98] (also reviewed in [99]).”
BackgroundBeumer‐Chuwonpad, A., Behr, F. M., van Alphen, F. P. J., Kragten, N. A. M., Hoogendijk, A. J., van den Biggelaar, M., & van Gisbergen, K. P. J. M. (2024) · European Journal of Immunology · doi:10.1002/eji.202350873 · Cited by 6
Hao, Z., Xin, Z., Chen, Y., Shao, Z., Lin, W., Wu, W., Lin, M., Liu, Q., Chen, D., Wu, P., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216839 · Cited by 6
Rationnel biologique de l’immunothérapie des cancers
Benzaquen, J., Marquette, C., Glaichenhaus, N., Leroy, S., Hofman, P. M., & Ilié, M. (2018) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.11.008 · Cited by 7
Parallel worlds of the adaptive and innate immune cell networks
Huang, Q., & Belz, G. T. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.04.008 · Cited by 6
Shang, Y., He, Y., Zhang, X., He, W., Hua, H., Feng, Y., Zhou, X., Li, Y., Zhong, W., Wu, G. S., et al. (2025) · Immunology · doi:10.1111/imm.13924 · Cited by 5
“…observed in a variety of solid tumours, such as head and neck squamous cell carcinoma (HNSCC) [76], oral squamous cell carcinoma (OSCC) [77], cervical cancer [78], lung cancer [79] and so on, confirming the potential role of TRMs for better prognosis due to a higher response rate to immunotherapy.”
Pesch, G., Piseddu, I., Gaertig, J., Kramer, N., Kramer, R., Schulz, T. U., Zwiebel, M., Ledderose, S., Retzlaff, J., Eckstein, M., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0387 · Cited by 7
CD49a+ NK cells promote esophageal cancer development by inducing MDSCs infiltration via GM-CSF
Cui, K., Hu, S., Zha, Y., Ding, K., Wei, H., Cheng, M., & Mei, X. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03065-7 · Cited by 5
Keeping it local: how CD8 TRMs regulate viral and cancer immunity
Rodrigues, L. C., Bonorino, C., Haubert, A. F., Lins, M. P., Pereira, G. P., Romão, P. R. T., & Rouse, B. T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1618700 · Cited by 5
Resident memory T cells in mouse and human
Watanabe, R. (2016) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.39.505 · Cited by 5
Newnes, H. V., Armitage, J. D., Audsley, K. M., Bosco, A., & Waithman, J. C. (2021) · Cancers · doi:10.3390/cancers13235911 · Cited by 5
Sato, H., Meng, S., Hara, T., Tsuji, Y., Arao, Y., Sasaki, K., Kobayashi, S., di Luccio, E., Hirotsu, T., Satoh, T., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12061342 · Cited by 5
“Although not previously reported in gastrointestinal cancers, CD8+CD103+ tumor-infiltrating lymphocytes are memory T cells that reside in tumor-specific tissues and are considered a prognostic factor for survival in lung cancer patients [44].”
BackgroundThe Role of HPV in the Development of Cutaneous Squamous Cell Carcinoma—Friend or Foe?
Dervenis, V. (2025) · Cancers · doi:10.3390/cancers17071195 · Cited by 5
Multifaceted functions of tissue-resident memory T cells in tumorigenesis and cancer immunotherapy
Seo, E. S., Lee, S., & Son, Y. M. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04035-x · Cited by 6
“…immune checkpoint receptors such as programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), lymphocyte activation gene 3 (LAG-3), T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) and T cell immunoglobulin and mucin domain 3 (TIM-3) [35, 48–51].”
Impact of multiple hits with cognate antigen on memory CD8+ T-cell fate
Takamura, S. (2020) · International Immunology · doi:10.1093/intimm/dxaa039 · Cited by 5
Hsiao, C., Kragten, N. A. M., Piao, X., Hamann, J., & van Gisbergen, K. P. J. M. (2021) · Cells · doi:10.3390/cells10102675 · Cited by 5
Kitakaze, M., Fujino, S., Miyoshi, N., Sekido, Y., Hata, T., Ogino, T., Takahashi, H., Uemura, M., Mizushima, T., Doki, Y., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-29260-1 · Cited by 5
Programmed T cell differentiation: Implications for transplantation
Crepeau, R. L., & Ford, M. L. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104099 · Cited by 5
Carlson, P. M., Mohan, M., Patel, R. B., Birstler, J., Nettenstrom, L. M., Sheerar, D. S., Fox, K. C., Rodriguez, M., Hoefges, A., Hernandez, R. T., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000656 · Cited by 5
Başoğlu, T., Akar, K. E., Bağcı, P., Babacan, N. A., Öztürk, M. A., Öztürk, F. E., Demircan, N. C., Arıkan, R., Telli, T. A., Erçelep, Ö., et al. (2021) · Balkan Medical Journal · doi:10.5152/balkanmedj.2021.21122 · Cited by 5
Barber, P. R., Mustapha, R., Flores‐Borja, F., Alfano, G., Ng, K., Weitsman, G. E., Dolcetti, L., Suwaidan, A. A., Wong, F., Vicencio, J. M., et al. (2022) · eLife · doi:10.7554/elife.73288 · Cited by 5
“We hypothesize that the predictive power of the population of peripheral CD8CM stems from its ability to home to the tumour and contribute to the Trm population which has recently been identified as key player in anti- tumour immunity in HNSCC as well as other cancers mainly in the context of immunotherapy but also in…”
BackgroundQi, C., Lei, L., Hu, J., & Ou, S. (2023) · Cell Cycle · doi:10.1080/15384101.2023.2205204 · Cited by 5
Tissue‐Resident Memory T Cells: Pioneering New Avenues in Cancer Immunotherapy
Xiao, Y., Yang, Q., & Sun, Z. (2025) · Cancer Medicine · doi:10.1002/cam4.71429 · Cited by 4
“Adhesion molecules on the surface of T RM , such as CD103, are associated with T cell anchoring within the tumor micro-environment and with infiltration into tumor epithelial islets [61, 62].”
Tissue-Resident Memory T Cells in Tumor Immunity and Immunotherapy of Digestive System Tumors
Cheng, M., Liu, J., Liang, Y., Xu, J., Ma, L., & Liang, J. (2025) · Immunological Investigations · doi:10.1080/08820139.2024.2447780 · Cited by 4
“According to research on TRM cells, CD8 + T cells expressing CD1May 3 be associated with a better prognosis in various epithelial malignancies (Djenidi et al., 2015; Edwards et al., 2018; R. Li et al., 2020; Webb et al., 2015).”
Liu, A., Liu, D., Liu, X., Chi, Y., Guo, L., Li, D., Wang, Q., Li, Y., Li, Y., Zheng, G., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-03988-3 · Cited by 4
“TRMs have been shown to directly mediate antitumor immunity by producing effector molecules and cytolytic mediators such as perforin and granzyme B (GzmB) [33, 34].”
Nishiyama, M., Miki, Y., Tanaka, H., Natsuki, S., Kuroda, K., Yoshii, M., Tamura, T., Toyokawa, T., Lee, S., & Maeda, K. (2025) · Cancer Science · doi:10.1111/cas.70163 · Cited by 4
Akbaba, H. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.90334 · Cited by 4
Zhao, S., Wu, S., Jiang, S., Zhou, X., Zhao, G., & Wang, B. (2023) · Scientific Reports · doi:10.1038/s41598-023-36884-w · Cited by 4
Sun, D., Hu, Y., Peng, J., & Wang, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062384 · Cited by 5
“…effectiveness of immunotherapy is associated with the type, quantity, and quality of T-cells present in the tumor site [5]. various tumor types [7,8], underscoring the importance of investigating Unlike other tumor types, PAAD exhibits higher immunogenicity and harbors large quantities of…”
Sun, W., Zhou, J., & Zhou, J. (2021) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.102.47 · Cited by 4
Yin, Z., Zhou, M., Liao, T.-T., Xu, J.-J., Fan, J., Deng, J.-J., & Jin, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.673567 · Cited by 3
Wei, W., Ding, Y., He, J., & Wu, J. (2022) · Biomedical Papers · doi:10.5507/bp.2022.016 · Cited by 5
Lama, G. I. G., Noel, G. L., López-Márquez, F. C., González-Galarza, F. F., Hinojosa, A. I. P., Nava‐Rivera, L. E., Willard-Gallo, K. E., & Arguello, J. R. (2023) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201025666230901094219 · Cited by 4
RNA biomarkers in cancer therapeutics: The promise of personalized oncology
Katifelis, H., & Gazouli, M. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2024.06.003 · Cited by 5
Park, S. L., & Mackay, L. K. (2017) · Immunology and Cell Biology · doi:10.1038/icb.2017.69 · Cited by 4
A unique epigenomic landscape defines CD8 + tissue-resident memory T cellsPreprint
Buquicchio, F. A., Fonseca, R., Belk, J. A., Evrard, M., Obers, A., Qi, Y., Dániel, B., Yost, K. E., Satpathy, A. T., & Mackay, L. K. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.04.490680 · Cited by 4
Going with the Flow: Circulating Tumor-Reactive Lymphocytes Stream into Cancer Therapy
Álvarez-Rodríguez, R., Vuchkovska, A., Wang, Z., Chartier, C., Hege, K. M., Kalos, M. D., & Kelley, S. O. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0882 · Cited by 3
Zhang, H., Luo, M., Feng, J., Tan, J., Jiang, Y., Frishman, D., & Liu, Y. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06860-1 · Cited by 5
“Despite ongoing debates regarding their role across various cancers [9], recent evidence underscores a positive correlation between TIL density and improved prognosis in LUAD in the context of immunotherapy [10–15].”
Corgnac, S., Damei, I., Gentile, C., Caidi, A., Badel, S., Phayanouvong, M., & Mami‐Chouaib, F. (2025) · iScience · doi:10.1016/j.isci.2025.113147 · Cited by 3
Self-citationLei, J., Ji, H., Guo, J., Liu, M., Su, D., Zheng, Y., Xu, L., Cao, Q., Ren, T., Gui, J., et al. (2025) · Advanced Science · doi:10.1002/advs.202513535 · Cited by 5
Cheng, C. Y., Sun, J., Lu, C., Yu, Q., He, Y., Wu, B., Ren, D., Ding, S., Zhao, J., & Li, Y. (2025) · Advanced Science · doi:10.1002/advs.202512097 · Cited by 3
Huang, Q., yang, D., Tao, Z., Yu, Z., Ding, W., Tao, N., Liao, X., Lin, H., Cheng, Z., Gao, S., et al. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1724792 · Cited by 3
Isomoto, K., Haratani, K., Tsujikawa, T., Tomida, S., Makutani, Y., Takeda, M., Yonesaka, K., Tanaka, K., Iwasa, T., Sakai, K., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci195021 · Cited by 3
“In addition, intratumoral CD103 + CD8 + T cells have been characterized as tumor-reactive T cells by their tissue residency and their frequent coexpression of other exhaustion markers (64).”
Shteinman, E. R., Attrill, G. H., Maher, N. G., Gnana, K., Addala, V., Mao, Y., Palendira, U., Conway, J. W., Colebatch, A. J., Waddell, N., et al. (2026) · Genome Medicine · doi:10.1186/s13073-026-01673-3 · Cited by 3
“While tumor-specific T cells (CD39 +) are generally associated with favourable outcomes in primary melanoma [54], additional tumor-specific TRMs have been linked to improved survival in metastatic melanoma [55] and a range of other cancers [56–61].”
(2021) · Frontiers research topics · doi:10.3389/978-2-88966-718-5 · Cited by 3
Wang, X., Fu, X., Liu, Q., Li, J., Ge, Y., Zhang, J., Wang, S., Wang, L., Wang, D., Sun, Y., et al. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03742-6 · Cited by 4
“Furthermore, CD103 + TRMs secrete abundant tumoricidal cytokines, including IFN-γ, TNF-α, perfo-rin-1, and granzyme B, to suppress tumor progression [35, 42].”
Huang, A., Wu, Y., Cui, J., Cai, M., Xie, Y., Zou, J., Alenzi, M., Yang, H., Huang, P., & Huang, M. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04087-z · Cited by 3
“…may serve as prognostic indicators for patients with CRC. Previous research has demonstrated a significant correlation between CD103 + cells and survival in NSCLC and ovarian cancer, without the need to discriminate their location in intraepithelial versus stromal compartments [12, 14].”
InfluentialShen, Y., Yeh, C.-P., Jeng, Y., Hsu, C., Hsu, C., Lin, Z., Shao, Y., Lu, L., Liu, T., Chen, C., et al. (2021) · Cancers · doi:10.3390/cancers13205142 · Cited by 3
[Advances in the Study of Tissue-resident Memory T Cells in Lung Cancer].
Tan, S., & Tian, P. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.102.49 · Cited by 3
CD103+ Cells and Chemokine Receptor Expression in Breast Cancer
Seo, E., Song, G.-Y., Oh, C.-S., Kim, S., Kim, W. S., & Lee, S. (2023) · Immune Network · doi:10.4110/in.2023.23.e25 · Cited by 3
“CD103+ cells and CD103− cells have different functions and surface receptor patterns (1,9).”
BackgroundInfluentialZuo, A., Lv, J., Jia, W., Ba, Y., Liu, S., Zhang, Y., Weng, S., Xu, H., Liu, L., Wang, L., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12916-0 · Cited by 4
“In patients with non-small cell lung cancer, TRM cells promote cytotoxic responses within tumors and support the rationale used to reverse tumor-induced T cell exhaustion in patients using anti-PD-1 antibodies [11].”
BackgroundResultRenauld, A., & Sverdlik, R. C. (1975) · PubMed · Cited by 4
Weeden, C. E., Gayevskiy, V., Trussart, M., Marceaux, C., Ribera, N. T., Batey, D., Teh, C. E., Mitchell, A. J., Antippa, P. N., Leong, T. L., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.20.440373 · Cited by 3
Wang, C., Wei, J., & Fang, D. (2021) · Research Square · doi:10.21203/rs.3.rs-422168/v1 · Cited by 3
Dynamic change of CD8+ T cell: immunotherapy fate tell?
Brueckl, W. M. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-139 · Cited by 3
A comprehensive reference of mouse CD8αβ T cell differentiation statesPreprint
Galletti, G., Globig, A.-M., Barreiro, O., Heim, T. A., Liu, S., Borys, S. M., Casey, O., Monell, A., Patravali, D., Scharping, N. E., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.02.703365 · Cited by 4
Metadata
- Authors
- Djenidi, F., Adam, J., Goubar, A., Durgeau, A., Meurice, G., de Montpréville, V., Validire, P., Besse, B., & Mami-Chouaib, F.
- Affiliations
- Université Paris-Sud (FR)
- INSERM Unité 1186 , 94805 Villejuif ,
- Institute Mutualiste Montsouris (FR)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-01
- Volume
- 194
- Issue
- 7
- Pages
- 3475-3486
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1895620535
- Cited by
- 622
- References
- 51
- Citations by year
- 2026: 34 · 2025: 61 · 2024: 51 · 2023: 55 · 2022: 63 · 2021: 81 · 2020: 72 · 2019: 70 · 2018: 66 · 2017: 27 · 2016: 28 · 2015: 13
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institut Gustave-Roussy
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-infiltrating lymphocytes, tissue-resident memory T cells, non-small cell lung cancer, PD-1, TIM-3, immune checkpoint blockade, T cell exhaustion, intraepithelial lymphocytes, patient survival, prognostic factors, T cell cytotoxicity
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Cytotoxicity, Immunologic, Female, Humans, Immunologic Memory, Lung Neoplasms, Lymphocyte Activation, Male, Membrane Proteins, Middle Aged, Neoplasm Staging, Organ Specificity, Prognosis, Risk Factors, Antigens, CD, Immunophenotyping, Lymphocytes, Tumor-Infiltrating, CD8 Antigens, Gene Expression Profiling, Integrin alpha Chains, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.